MaxisIT, a leader in AI-powered clinical trial technologies, today announced the release of Site Copilot, the latest innovation built on the cutting-edge DTect AI platform under MaxisIT's Agentic AI suite. Site Copilot is a conversational AI agent designed to address critical challenges faced by clinical trial sites, such as regulatory compliance, quality management, and patient engagement, while streamlining workflows and improving sponsor-site collaboration.
Although eConsent, eSource, Patient engagement tools, eISF and eTMF are increasingly adopted, the workflow remains broken due to siloed systems. These fragmented workflows create inefficiencies, slower responses to compliance issues, and risks in data quality and patient engagement. Site Copilot seamlessly integrates into workflows without any additional technology burden, empowering staff with actionable insights and recommendations through natural language conversations.
Site Copilot Features:
● Detects and reports anomalous data, trends, events, risks, and actions in the clinical research workflow.
● Recommends the next best action to rectify such anomalies, mitigate risks and improve outcomes by keeping human-in-the-loop.
● Calculates overall "Quality Score" and "Risk Score" of the site by continuously assessing evolving scenarios on an autonomous basis.
● Drives more accurate and reliable results by reducing the risk of incorrect conclusions and transitioning to hybrid workflows managed by AI and AI-augmented site staff.